TITLE

Genmab Further Validates its DuoBodyâ„¢ Technology with Janssen Biotech Agreement

AUTHOR(S)
Cartwright, Heather
PUB. DATE
July 2012
SOURCE
PharmaDeals Review;2012, Vol. 2012 Issue 7, p103
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Genmab has made further progress with its DuoBodyâ„¢ technology platform by agreeing to collaborate with Johnson & Johnson's Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront plus potential milestone and licence payments of up to US$175 M for each product successfully developed from the collaboration as well as royalties on sales of any commercialised products. Amgen's US$1.16 B acquisition of Micromet in March 2012 fuelled industry interest in bispecific antibody technologies
ACCESSION #
79242488

 

Related Articles

  • Companies wager high on CD38-targeting drugs for blood cancer. Hersher, Rebecca // Nature Medicine;Oct2012, Vol. 18 Issue 10, p1446 

    The article informs that GenMab A/S has signed a 1.1 billion U.S. dollars contract for licensing rights for its blood cancer drug daratumumab with Janssen Biotech Inc., a subsidiary of the company Johnson & Johnson. It informs that the drug developers have an emerging class of medicines which...

  • Genmab, J&J in $175M Per Product DuoBody Deal. Sheridan, Cormac // BioWorld International;7/18/2012, Vol. 17 Issue 29, p1 

    The article reports on a broad collaboration between Genmab A/S and Johnson & Johnson (J&J) subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets.

  • A 'Brilliant' Deal.  // BioWorld International;9/5/2012, Vol. 17 Issue 36, p4 

    This article reports on the partnership formed by Genmab A/S with Janssen Biotech Inc. for its anti-CD38 monoclonal antibody daratumumab.

  • Genmab and Sanquin collaborate on hemophilia research.  // PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p11 

    Reports that Genmab AS has entered into a research venture with the Sanquin Blood Supply Foundation to develop and improve hemophiliac treatment. Discovery of a method for preventing inhibitory antibodies from binding to factor VIII therapy; Utilization of antibodies to block the sites where the...

  • Genmab, J&J in $175M Per Product DuoBody Deal. Sheridan, Cormac // BioWorld Today;7/16/2012, Vol. 23 Issue 136, p1 

    The article reports on the collaboration of Genmab A/S with Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets. The deal, which could involve up to 10 separate programs, is said to represent additional validation for Genmab's specific antibody platform,...

  • Genmab Lands $1.1B Cancer Deal with 'Perfect Partner' J&J. Moran, Nuala // BioWorld Today;8/31/2012, Vol. 23 Issue 170, p1 

    The article reports on a worldwide commercialization deal signed by Genmab A/S with Janssen Biotech Inc. for the anti-CD38 monoclonal antibody daratumumab. The terms of the deal include Jansen paying for all costs of developing the drug and its participation in a development plan involving 10 or...

  • Genmab Lands $1.1B Cancer Deal with 'Perfect Partner' J&J. Moran, Nuala // BioWorld International;9/5/2012, Vol. 17 Issue 36, p1 

    This article reports on the partnership formed by Genmab A/S with Janssen Biotech Inc. for its anti-CD38 monoclonal antibody daratumumab. The deal is valued at more than 1.1 billion U.S. dollars and involves a worldwide commercialization of the product. The product is currently in two Phase I/II...

  • GENMAB/ROCHE ANNOUNCE ANTIBODY DEVELOPMENT COLLABORATION.  // Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p7 

    Announces the broad collaboration of Genmab A/S with the Roche company for the creation and development of human antibody therapeutics.

  • A 'Brilliant' Deal.  // BioWorld Today;8/31/2012, Vol. 23 Issue 170, p4 

    The article reports on the interest of pharmaceutical companies in the anti-CD38 monoclonal antibody daratumumab of Genmab A/S. According to chief executive officer (CEO) Jan van Winkel, they received term sheets from various parties for the drug. Information on the company's deal with Jansen...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics